Cargando…

Peginterferon plus weight-based ribavirin for treatment-naïve hepatitis C virus genotype 2 patients not achieving rapid virologic response: a randomized trial

Hepatitis C virus genotype 2 (HCV-2) slow responders poorly respond to 24 weeks of peginterferon (Peg-IFN) plus ribavirin (RBV). We evaluated the efficacy of extended 48-week regimen and the role of interleukin-28B (IL-28B) genotype in this clinical setting. Treatment-naïve HCV-2 patients not achiev...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Chen-Hua, Huang, Chung-Feng, Liu, Chun-Jen, Dai, Chia-Yen, Huang, Jee-Fu, Lin, Jou-Wei, Liang, Cheng-Chao, Yang, Sheng-Shun, Lin, Chih-Lin, Su, Tung-Hung, Yang, Hung-Chih, Chen, Pei-Jer, Chen, Ding-Shinn, Chuang, Wan-Long, Kao, Jia-Horng, Yu, Ming-Lung
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2015
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4486927/ https://www.ncbi.nlm.nih.gov/pubmed/26130141 http://dx.doi.org/10.1038/srep11710

Ejemplares similares

Peginterferon alfa-2a plus Weight-Based or Flat-Dose Ribavirin for Treatment-Naïve Hepatitis C Virus Genotype 2 Rapid Responders: A Randomized Trial
por: Liu, Chen-Hua, et al.
Publicado: (2015)

Peginterferon plus Ribavirin for HIV-infected Patients with Treatment-Naïve Acute or Chronic HCV Infection in Taiwan: A Prospective Cohort Study
por: Liu, Chen-Hua, et al.
Publicado: (2015)

Identification of groups with poor cost-effectiveness of peginterferon plus ribavirin for naïve hepatitis C patients with a real-world cohort and database
por: Tsai, Pei-Chien, et al.
Publicado: (2017)

Revisiting the Stopping Rule for Hepatitis C Genotype 1 Patients Treated with Peginterferon Plus Ribavirin
por: Yu, Ming-Lung, et al.
Publicado: (2012)

Dynamics of PBMC gene expression in hepatitis C virus genotype 1-infected patients during combined peginterferon/ribavirin therapy
por: Lu, Ming-Ying, et al.
Publicado: (2016)

Real-world effectiveness and safety of sofosbuvir and ledipasvir with or without ribavirin for patients with hepatitis C virus genotype 1 infection in Taiwan
por: Liu, Chen-Hua, et al.
Publicado: (2018)

Elevated on-treatment levels of serum IFN-gamma is associated with treatment failure of peginterferon plus ribavirin therapy for chronic hepatitis C
por: Lu, Ming-Ying, et al.
Publicado: (2016)

Association of SCARB1 Gene Polymorphisms with Virological Response in Chronic Hepatitis C Patients Receiving Pegylated Interferon plus Ribavirin Therapy
por: Hsu, Ching-Sheng, et al.
Publicado: (2016)

Peginterferon Alfa-2a Is Associated with Elevations in Alanine Aminotransferase at the End of Treatment in Chronic Hepatitis C Patients with Sustained Virologic Response
por: Tseng, Chih-Wei, et al.
Publicado: (2014)

Durability of a sustained virologic response in patients with chronic hepatitis C treated with peginterferon and ribavirin
por: Kim, Kyung-Ah
Publicado: (2011)

Long-Term Effect of Interferon Plus Ribavirin on Hepatitis B Surface Antigen Seroclearance in Patients Dually Infected with Hepatitis B and C Viruses
por: Yeh, Ming-Lun, et al.
Publicado: (2011)

Sustained virological response in HIV/HCV co-infected patients without rapid virological response (RVR) on peginterferon-ribavirin therapy
por: Labarga, P, et al.
Publicado: (2010)

Neutrophil-to-Lymphocyte Ratio as a Predictor of Response to Peginterferon plus Ribavirin Therapy for Chronic Hepatitis C
por: Kuo, Ming-Te, et al.
Publicado: (2014)

Rapid Prediction of Treatment Futility of Boceprevir with Peginterferon-Ribavirin for Taiwanese Treatment Experienced Hepatitis C Virus Genotype 1-Infected Patients
por: Yang, Chi-Chieh, et al.
Publicado: (2015)

Hepatitis C Virus Reinfection in People With HIV in Taiwan After Achieving Sustained Virologic Response With Antiviral Treatment: The RECUR Study
por: Liu, Chen-Hua, et al.
Publicado: (2022)

Assessment of the Efficacy of Reducing Peginterferon Alfa-2a and Ribavirin Dose on Virologic Response in Koreans with Chronic Hepatitis C
por: Kwon, Jung Hyun, et al.
Publicado: (2009)

Prediction of Treatment Week Eight Response & Sustained Virologic Response in Patients Treated with Boceprevir Plus Peginterferon Alfa and Ribavirin
por: Thompson, Alex, et al.
Publicado: (2014)

Increased Baseline Proinflammatory Cytokine Production in Chronic Hepatitis C Patients with Rapid Virological Response to Peginterferon Plus Ribavirin
por: Par, Gabriella, et al.
Publicado: (2013)

Peginterferon plus ribavirin and sustained virological response rate in HCV-related advanced fibrosis: a real life study
por: Silva, Giovanni Faria, et al.
Publicado: (2013)

Hepatitis B Virus Reactivation in Patients Receiving Interferon-Free Direct-Acting Antiviral Agents for Chronic Hepatitis C Virus Infection
por: Liu, Chen-Hua, et al.
Publicado: (2017)

Cost-Efficacy Analysis of Peginterferon alfa-2b plus Ribavirin Compared With Peginterferon alfa-2a plus Ribavirin for the Treatment of Chronic Hepatitis C
por: Malone, Daniel C., et al.
Publicado: (2005)

Ribavirin Enhances the Action of Interferon-α against Hepatitis C Virus by Promoting the p53 Activity through the ERK1/2 Pathway
por: Liu, Wei-Liang, et al.
Publicado: (2012)

Predictive factors for 24 weeks sustained virologic response (SVR24) and viral relapse in patients treated with simeprevir plus peginterferon and ribavirin
por: Nakayama, Masahiko, et al.
Publicado: (2015)

Longitudinal Change of HBsAg in HBeAg-negative Patients with Genotype B or C Infection
por: Su, Tung-Hung, et al.
Publicado: (2013)

Efficacy and Tolerability of Peginterferon α-2a and Peginterferon α-2b, Both plus Ribavirin, for Chronic Hepatitis C: A Meta-Analysis of Randomized Controlled Trials
por: Yang, Zongguo, et al.
Publicado: (2013)

Chronic HCV treatment with peginterferon-ribavirin and severe tuberculosis re-activation
por: Manfredi, Roberto, et al.
Publicado: (2010)

Is peginterferon and ribavirin therapy effective in Korean patients with chronic hepatitis C?
por: Jung, Young Kul, et al.
Publicado: (2013)

Sustained Virologic Response to Peginterferon α-2a and Ribavirin in 335 Patients with Chronic Hepatitis C: A Tertiary Care Center Experience
por: Al Ashgar, Hamad, et al.
Publicado: (2008)

High Rate of Virological Response to Peginterferon α-2a–Ribavirin Among Non-Cirrhotic Iranian Hemophilia Patients With Chronic Hepatitis C
por: Alavi Moghaddam, Mostafa, et al.
Publicado: (2012)

Characterization of nonrapid virologic response patients infected with HCV genotype 1 who may relapse after standard therapy with peginterferon plus ribavirin
por: Reau, N, et al.
Publicado: (2012)

Treatment-emergent depression and anxiety between peginterferon alpha-2a versus alpha-2b plus ribavirin for chronic hepatitis C
por: Wang, Liang-Jen, et al.
Publicado: (2016)

Nanomedicines in the treatment of hepatitis C virus infection in Asian patients: optimizing use of peginterferon alfa
por: Liu, Chen-Hua, et al.
Publicado: (2014)

24 versus 48 Weeks of Peginterferon Plus Ribavirin in Hepatitis C Virus Genotype 6 Chronically Infected Patients with a Rapid Virological Response: A Non-Inferiority Randomized Controlled Trial
por: Cai, Qingxian, et al.
Publicado: (2015)

SVR12 is higher than SVR24 in treatment-naïve hepatitis C genotype 1 patients treated with peginterferon plus ribavirin
por: Thorlund, Kristian, et al.
Publicado: (2014)

Aspartate aminotransferase to platelet ratio index and sustained virologic response are associated with progression from hepatitis C associated liver cirrhosis to hepatocellular carcinoma after treatment with pegylated interferon plus ribavirin
por: Ng, Khai-Jing, et al.
Publicado: (2016)

Cirrhosis and Rapid Virological Response to Peginterferon Plus Ribavirin Determine Treatment Outcome in HCV-1 IL28B rs12979860 CC Patients
por: Aghemo, Alessio, et al.
Publicado: (2013)

Sustained Virologic Response to a Dual Peginterferon alfa-2a and Ribavirin in Treating Chronic hepatitis C Infection: A Retrospective Cohort Study
por: Naing, Cho, et al.
Publicado: (2015)

Once-daily simeprevir (TMC435) with peginterferon/ribavirin for treatment-naïve hepatitis C genotype 1-infected patients in Japan: the DRAGON study
por: Hayashi, Norio, et al.
Publicado: (2013)

Cost Effectiveness of Daclatasvir/Asunaprevir Versus Peginterferon/Ribavirin and Protease Inhibitors for the Treatment of Hepatitis c Genotype 1b Naïve Patients in Chile
por: Vargas, Constanza L., et al.
Publicado: (2015)

Personalized Therapy of Chronic Hepatitis C and B Dually Infected Patients With Pegylated Interferon Plus Ribavirin: A Randomized Study
por: Yeh, Ming-Lun, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_vvhlqa7286o24ma4bfq5sqi1k1